Symposium

Antimicrobial Optimization in the ICU: Treating HABP/VABP in the Critically Ill Patient - This program is supported by educational grants from AbbVie and Merck Sharp & Dohme Corp

Tuesday, April 19, 2022

12:00 PM – 1:00 PM US CST

CE: 1.0

Symposium Faculty(s)

CB

Christopher Bland

Clinical Professor
University of Georgia College of Pharmacy
Savannah, Georgia, United States

Speaker's Bureau - Merck Pharmaceuticals, Biomerieux; Consultant - Merck Pharmaceuticals
TC

Tatjana Calvano, MD

Brooke Army Medical Center
Joint Base Lewis-McChord

No relevant financial relationship(s) to disclose

The goal of this activity is to improve the knowledge and competence of healthcare providers about the diagnosis, treatment, and management of HABP/VABP in critically ill patients.

This program is supported by educational grants from AbbVie and Merck Sharp & Dohme Corp.

Learning Objectives:

Describe the role of rapid diagnostics in HABP/VABP caused by MDR gram-negative infections
Appropriately use new antimicrobial agents for both empiric and targeted therapy in MDR gram-negative HABP/VABP
Identify strategies for managing critically ill patients with unique clinical scenarios, such as augmented or diminished renal clearance
Implement effective approaches to antimicrobial stewardship and minimizing TTET